Integrated Biopharma, Inc.
INBP
$0.30
$0.00-0.27%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.58% | -6.82% | 11.21% | 6.09% | 9.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.58% | -6.82% | 11.21% | 6.09% | 9.60% |
| Cost of Revenue | -1.68% | -4.70% | 10.85% | 4.18% | 4.13% |
| Gross Profit | -97.52% | -25.67% | 14.41% | 24.28% | 125.19% |
| SG&A Expenses | -2.68% | -2.84% | -0.23% | -9.07% | -0.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.76% | -4.58% | 10.06% | 3.25% | 3.77% |
| Operating Income | -552.48% | -66.73% | 46.52% | 108.17% | 144.69% |
| Income Before Tax | -572.43% | -61.11% | 43.72% | 121.02% | 140.93% |
| Income Tax Expenses | -262.32% | -70.20% | 429.45% | 149.25% | 198.57% |
| Earnings from Continuing Operations | -756.90% | -52.51% | -166.42% | 114.39% | 130.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -756.90% | -52.51% | -166.42% | 114.39% | 130.37% |
| EBIT | -552.48% | -66.73% | 46.52% | 108.17% | 144.69% |
| EBITDA | -393.33% | -58.26% | 38.36% | 88.66% | 176.20% |
| EPS Basic | -744.74% | -53.49% | -165.17% | 112.63% | 129.92% |
| Normalized Basic EPS | -500.00% | -62.86% | 43.02% | 109.59% | 147.31% |
| EPS Diluted | -889.47% | -54.65% | -165.17% | 110.53% | 129.92% |
| Normalized Diluted EPS | -509.30% | -62.14% | 46.43% | 108.45% | 146.24% |
| Average Basic Shares Outstanding | 2.93% | 3.19% | 1.70% | 0.67% | 0.25% |
| Average Diluted Shares Outstanding | -0.78% | 2.52% | -0.30% | 2.51% | 4.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |